1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
SB Technology Holdings, Inc.

SB Technology Holdings, Inc.

VGLS
SB Technology Holdings, Inc.US flagOther OTC
0.40
USD
-0.59
- -
421,910.00Market Cap
SB Technology Holdings, Inc.
VGLS
(Other OTC)

Recent

price

0.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2001
2001
2002
2003
2004
2005
2006
2013
2014
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-12.22
-25.61
-27.53
-61.7
-69.27
-29.67
-72.25
-0.91
-0.22
-0.06
Basic EPS, GAAP
-9.56
-6.86
-4.23
-13.58
-11.81
-19.78
-22.91
-0.13
-0.07
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-524.28
-158.25
-157.35
-202.72
-214.86
-169.29
-309.67
-12.18
-3.83
-1.62
Book Value per Share
-188.47
-175.87
-146.42
-134.19
-9.3
-12.82
-41.97
-0.68
-0.2
-0.08
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
8
28
68
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-2
-4
-7
-5
-13
-7
-6
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-7
-2
1
-1
-6
-6
-6
-5
Working Capital
8
9
3
8
2
2
2
- -
- -
- -
LT Debt
-3
-4
-4
-4
4
3
-7
-4
-5
-4
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
ST Debt
4
4
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
77
102
Market Capitalization
48,234
63,810
66,706

Working Capital

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
6
5
Payables & Accruals
1
1
1
ST Debt
4
4
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-117.7%
0.84%
Free Cash Flow
- -
43.97%
83.96%
Net Income, GAAP
- -
27.99%
-16.58%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
-4.73
-4.37
-0.18
-0.91
2014
-0.14
-0.09
-0.04
- -
-0.22
2015
-0.03
-0.02
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
Similar Companies
SMS Lifesciences India Limited (SMSLIFE.NS)
Roivant Sciences Ltd. (ROIVW)
Compass Therapeutics, Inc. (CMPX)
FluoroPharma Medical, Inc. (FPMI)
Cambium Bio Limited (CMB.AX)
Royalty Pharma plc (RPRX)
Business
VG Life Sciences Inc. VG Life Sciences Inc. (VGLS), a holding company and subsidiary of KH Feelux Co., Ltd., restructures its business to focus on real estate investment, acquisitions, development, and value-added opportunities; it previously operated as a biotechnology firm researching and developing transformative therapies for cancer, infectious diseases, and autoimmune conditions caused by chronic inflammation. The company offers targeted peptide technology (TPT) to eliminate pro-inflammatory immune cells for autoimmune and infectious diseases; VG1177, a synthesized peptide solution that binds to and removes Class II-associated invariant chain peptide (CLIP) on specific B cells to reduce chronic inflammation; and metabolic disruption technology (MDT) compounds, including Hydroxychloroquine, which sensitize drug-resistant cancer cells to treatment by disrupting tumor cell metabolism. Founded in 1995 and headquartered at 121 Gray Avenue, Suite 200, Santa Barbara, California, VG Life Sciences maintains minimal operations with one full-time employee and engages primarily in the U.S. real estate sector following its strategic pivot away from biotech activities. In recent years, the company changed its name from Viral Genetics Inc. in November 2012 and shifted focus to real estate restructuring, as indicated in ongoing profiles and market discussions from 2023-2025, with no major new acquisitions, partnerships, or funding rounds reported in the last 1-2 years.